Johnson & Johnson $JNJ Stock: Fulcrum Asset Management LLP Grows Position

Key Points

• Fulcrum Asset Management increased its Johnson & Johnson position by 57.4% in the third quarter, to 32,760 shares valued at about $8.77 million. Institutional investors collectively own 69.55% of the stock.
• J&J’s latest quarterly results topped expectations: EPS was $2.59 versus $2.53 expected, while revenue rose 5.9% year over year to $25.40 billion. The company set 2026 EPS guidance of $11.05–$11.15.
• Analysts’ consensus rating is “Moderate Buy,” with an average target price of $275.92. The company also declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% annualized yield.

Fulcrum Asset Management LLP lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 57.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,760 shares of the company's stock after acquiring an additional 11,945 shares during the period. Fulcrum Asset Management LLP's holdings in Johnson & Johnson were worth $8,766,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Jupiter Topco LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at $1,967,399,000. Corient Private Wealth LP boosted its stake in Johnson & Johnson by 127.3% during the 2nd quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company's stock worth $1,539,292,000 after purchasing an additional 3,393,981 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock worth $5,736,851,000 after buying an additional 2,513,321 shares in the last quarter. Amundi grew its holdings in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Finally, SEB Asset Management AB purchased a new stake in shares of Johnson & Johnson during the first quarter worth $314,468,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Argus set a $300.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a research note on Thursday, October 15th. Scotiabank reiterated an "outperform" rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $275.00 to $287.00 and gave the stock an "overweight" rating in a research note on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $276.14 on Monday. The stock's fifty day moving average is $265.91 and its two-hundred day moving average is $248.30. The firm has a market capitalization of $664.76 billion, a P/E ratio of 41.84, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the company earned $2.80 EPS. The company's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.